Shots: Under the amended agreement, the offer price increased from $44.5 to $49/QIAGEN share in cash, representing a premium of 35% to the closing price of QIAGEN’s ordinary shares on […]readmore
Tags : Acquire
Shots: Gilead to receive an up front in cash and convertible notes into Kronos equity, regulatory & commercial milestones along with royalties on sales of products emerges from the acquired […]readmore
Shots: Medtronic to acquire all outstanding shares of Medicrea along with its MEDICREA UNiD ASI for about $7.98/ share with a premium of 22% over the closing price of shares […]readmore
Shots: uniQure to receive $2B+ including $450M as up front in cash, $1.6B as regulatory & commercial milestones along with royalties in sales of AMT-061 (etranacogene dezaparvovec) while CSL Behring […]readmore
Shots: Novo Nordisk to acquire in all-cash transaction, making a total deal value ~$2.1B which included $725M as upfront and a remaining as regulatory and sales milestones The acquisition of […]readmore
Shots: Cipla to acquire 21.85% stake in GoApptiv on a fully diluted basis for ~1.2M (₹9 crores) which included ₹5.80 crores in the first stage and ₹3.20 crores in the […]readmore
Shots: Melilnta to acquire Tetraphase for $39M in cash along with $16M in cash under CVRs upon the achievement of net sales of XERAVA in the US of at least […]readmore
Shots: Under the amended agreement, AcelRx to acquire Tetraphase for $30M ($24.6M in stock and $5.4M in cash) with an additional $14.5M in CVRs, payable in cash. The transaction is […]readmore
Shots: Shionogi to acquire Tetra for a total value of up to $500M which includes regulatory and commercial milestones, based on certain achievements. Following the acquisition, Shionogi will get global […]readmore
Shots: Merck Animal Health to acquire the US rights to Sentinel flavor tabs and chews in the companion animal category, under the agreement with Virbac. The transaction is expected to […]readmore